couter

ALLRAllarity Therapeutics, Inc.

Allarity Therapeutics, Inc. (ALLR) sells stenoparib, a drug in Phase 3 development for relapsed small cell lung cancer and advanced ovarian cancer, under FDA Fast Track status. The next catalyst is Nov 13, 2026 — Q3 2026 Earnings Release and R&D Update, which will test the company’s ability to deliver clinical data and financial clarity amid a cash burn and long trial timelines.

  • The company has $29.8M in cash as of Q2 2026, but free cash flow is negative and debt-to-equity is 2.4x.
  • Stenoparib’s development is the core of the business, with no near-term revenue.
  • The stock is testing its ability to sustain a long runway without clinical progress.
Nov 13, 2026 — Q3 2026 Earnings Release and R&D Update
Chart by TradingView

The schedule

  • Fri13Nov

    The earnings release and R&D update will test the company's ability to provide clarity on its clinical progress and cash burn, which are critical for maintaining investor confidence and managing market expectations.

  • Tue15Dec

    The pipeline strategy and 2027 outlook will test the company's ability to outline its long-term plans and progress on key clinical trials, which will be crucial for maintaining investor confidence and securing future capital.

  • Tue2Feb

    Allarity is expected to provide a mid-year update on its clinical progress for stenoparib and its companion diagnostic pipeline. With shares trading near the 52-week high of $1.97, the market is pricing in a favorable readout. A strong update could push the stock to $2.10, while delays or mixed efficacy data would likely see shares revert to the 50-day SMA around $1.20.

  • Fri12Feb

    The earnings release will test whether Allarity can deliver a positive guidance reset, particularly on cash burn and clinical progress, following the last print where revenue missed estimates due to delayed trials.

  • Fri14May

    This release will test the company's ability to show progress on its oncology pipeline, particularly with any new data from Phase 2 trials, which will be critical for investor sentiment and fundraising efforts.

  • Fri13Aug

Past

  • Tue15Sep

    Actual outcome: Mixed · $1.17 at outcome

    The stock closed at $1.17 on the outcome date, representing a 1.7% rise from the event date, aligning with the bull case. The market reacted positively to the potential equity financing or ATM utilization, which signaled continued support for clinical trials and strategic growth. While no specific earnings results were mentioned, the anticipation of capital to fund operations reinforced investor confidence, moving the price toward the bull target.

    Market anticipation of a dilutive capital raise or strategic funding package to support ongoing clinical trials.

  • Fri15May

    Actual outcome: Mixed · $1.34 at outcome

    Allarity reported Q1 2026 EPS of -$0.17, exactly in line with estimates, and highlighted the ongoing clinical development of stenoparib for advanced ovarian and small cell lung cancers. Despite positive updates regarding a new intellectual property allowance for its companion diagnostic and a solid $29.8 million cash position, the lack of major new clinical data or surprises led to a muted market reaction, leaving the stock essentially flat.

    Q1 2026 earnings release and quarterly pipeline execution update.

  • Fri15May

    Actual outcome: Bear · $1.49 at outcome

    Allarity Therapeutics reported in-line earnings with an EPS of -$0.17, matching analyst estimates, and highlighted a cash position of $29.8 million. While the company noted its Phase 3 manufacturing campaign for stenoparib is on track for completion by the third quarter of 2026 to support a pivotal ovarian cancer trial, the stock declined. The bearish reaction was driven by the lack of immediate clinical data breakthroughs and the extended timeline before pivotal trial initiation, leaving investors cautious about the long wait for potential commercialization.

    Q2 earnings will bring intense focus to the company's cash burn and balance sheet, particularly regarding the elevated debt balance. Maintaining guidance on near-term readouts and cash preservation could support a target of $2.40, while an adverse print reflecting higher-than-expected burn could trigger a sell-off to $1.50.